

The Immunological Basis for Immunization Series

Module 5: Tuberculosis

Immunization, Vaccines and Biologicals



**World Health
Organization**

The Immunological Basis for Immunization Series

Module 5: Tuberculosis

Immunization, Vaccines and Biologicals



**World Health
Organization**

WHO Library Cataloguing-in-Publication Data

The immunological basis for immunization series: module 5: tuberculosis.

(Immunological basis for immunization series ; module 5)

1.Tuberculosis - prevention and control. 2.Tuberculosis -microbiology. 3.Tuberculosis - immunology. 4.BCG vaccine - therapeutic use. 5.BCG Vaccine - adverse effects. 6.Vaccination. I.World Health Organization. II.Series.

ISBN 978 92 4 150241 2

(NLM classification: WF 200)

© World Health Organization 2011

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

**The Department of Immunization, Vaccines and Biologicals
thanks the donors whose unspecified financial support
has made the production of this document possible.**

This module was produced for Immunization, Vaccines and Biologicals, WHO, by:

Lewellys F. Barker
Aeras Global TB Vaccine Foundation, Rockville MD, USA
Gregory Hussey
University of Cape Town, Cape Town, South Africa

Printed in October 2011

**Copies of this publication as well as additional materials
on immunization, vaccines and biological may be requested from:**

World Health Organization
Department of Immunization, Vaccines and Biologicals
CH-1211 Geneva 27, Switzerland
• Fax: + 41 22 791 4227 • Email: vaccines@who.int •

© World Health Organization 2011

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

The named authors alone are responsible for the views expressed in this publication.

Printed by the WHO Document Production Services, Geneva, Switzerland

Contents

<i>Abbreviations and acronyms</i>	<i>v</i>
<i>Preface</i>	<i>vii</i>
1. TB disease	1
2. Bacteriology	3
3. The host response to infection	5
4. Characteristics of BCG vaccines	7
5. Response to vaccination with BCG vaccines	9
<i>5.1 Route of administration of BCG vaccines</i>	<i>9</i>
<i>5.2 BCG vaccination scars</i>	<i>10</i>
<i>5.3 Delayed type hypersensitivity reactions and cell-mediated response</i>	<i>11</i>
<i>5.4 Adverse events</i>	<i>11</i>
<i>5.5 Protective efficacy and duration of immunity</i>	<i>13</i>
6. Future prospects	18
References	20

Abbreviations and acronyms

AIDS	acquired immunodeficiency syndrome
BCG	bacille Calmette-Guérin (vaccine)
CFU	colony-forming units
CI	confidence interval
DOTS	WHO-recommended directly observed treatment tuberculosis control strategy
DTH	delayed type hypersensitivity
ELISPOT	enzyme-linked immunospot assay
EPI	Expanded Programme on Immunization
GACVS	Global Advisory Committee on Vaccine Safety (WHO)
HIV	human immunodeficiency virus
HLA	human leukocyte antigen
IGRA	interferon gamma release assay
IFN- γ	interferon-gamma
IL-2	interleukin-2
LTBI	latent tuberculosis infection
M.	Mycobacterium
MDR-TB	multi drug-resistant tuberculosis
MRC	Medical Research Council (United Kingdom)
Mtb	Mycobacterium tuberculosis
NRAMP	natural resistance associated monocyte protein
PBMC	peripheral blood mononuclear cells
PPD	purified protein derivative
RD1	deletion region 1
SCID	severe combined immunodeficiency

TB	tuberculosis
TH1/2	T helper cells type 1/2
TNF- α	tumour necrosis factor-alpha
ToC	test-of-concept (trial)
TST	tuberculin skin test
WHO	World Health Organization
USA	United States of America
XDR-TB	extensively drug-resistant tuberculosis

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_28643

